The FDA approved Zongertinib for adults with unresectable or metastatic non-squamous NSCLC with HER2 (ERBB2) TKD activating mutations following prior systemic therapy.
The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...
The US Food and Drug Administration has approved the first treatment for a genetic mutation of non-small cell lung cancer, and also approved the diagnostic test for determining multiple genetic mutations...
The FDA approved the first anti-PD-1 therapy to be administered in combination with standard chemotherapy for the treatment of non-small cell lung cancer.
The FDA approved osimertinib for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...
